The Cancer Genome Sequencing Market report is equipped with market data from 2013 to 2023. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2018 to 2023. The detailed sales channel is also covered in the study.
Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells.
Scope of the Report:
This report studies the Cancer Genome Sequencing market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Genome Sequencing market by product type and applications/end industries.
It is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal / fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites. This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations.
The global Cancer Genome Sequencing market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Genome Sequencing.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Agilent Technologies
- GE Healthcare Life Sciences
- Johnson & Johnson
- LI-COR Biosciences
- Abbott Laboratories
- Beckman Coulter
- Bayer Corporation
- Hamilton Thorne Biosciences
Microchip Biotechnologies
- Myriad Genetics
- Commonwealth Biotechnologies
- ZS Genetics
- Pacific Biosciences
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Second generation
- Third generation
Market Segment by Applications, can be divided into